Navigation Links
Pioneering research into rare neonatal diseases
Date:8/13/2012

Groundbreaking research into rare neonatal diseases, conducted by the University of Sheffield, is set to improve the treatment of babies who lack the stress hormone cortisol.

A European Union grant, awarded to the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust with pharmaceutical Diurnal Ltd and partners, will assist the development of a novel neonatal formulation of hydrocortisone a steroid drug that is essential for the survival of babies who lack the hormone cortisol.

Known as the stress hormone, cortisol is secreted from the adrenal gland in the body - without it infants cannot survive. Cortisol has a critical role in combating infections or other sources of physical stress such as extreme exercise or surgery.

The most common cause of adrenal insufficiency in neonates is congenital adrenal hyperplasia (CAH). Approximately 1 in every 12,000 children is born with CAH which is a rare genetic disorder that blocks the adrenal glands' ability to synthesise cortisol.

Due to numerous ethical and practical challenges of testing medications, newborns, neonates and infants are often thought to be at a disadvantage when it comes to new medical treatment, because they have to be treated with drugs that were developed for adults.

Professor Richard Ross from the University of Sheffield's Medical School said: "Adrenal insufficiency is a serious condition resulting from a lack of stress hormone cortisol, and untreated patients will die from an adrenal crisis.

"Currently there is no licensed preparation to treat neonates and infants with adrenal insufficiency, and parents have to use crushed adult tablets, which have associated risks of over- and under-treatment. Under-treatment can be potentially lethal, while over-treatment results in growth failure and obesity."

The European collaborative project Treatment of Adrenal Insufficiency in Neonates and Infants (TAIN) Development of Hydrocortisone Preparation for the Treatment of Adrenal Insufficiency in Neonates and Infants, began in December 2011 and involves European leaders in neonatology, paediatric pharmacology and clinical trial methodology, together with a number of small and medium enterprises.

Professor Ross added: "The TAIN project will deliver the first licensed preparation specifically designed for parents to treat their babies with ease of administration, taste masking and appropriately tailored doses.

"As physicians, we are increasingly aware that treatments given as early in life as possible can have an important impact on development and health later in life. TAIN aims to optimise treatment for babies with adrenal insufficiency, and will strengthen paediatric drug evaluation across Europe by building a network of units experienced in clinical research delivering appropriate formulations for neonates and infants."

TAIN coordinator, Martin Whitaker from the University of Sheffield, said: "The funding of the TAIN programme by the European Commission will, for the first time, allow the possibility to develop an effective paediatric medicine for the rare disease adrenal insufficiency.

"The outcomes of TAIN will make a real and significant difference to the loves of young children suffering from this disease, who currently have to rely on unlicensed, sub-optimal medications.

The TAIN project also includes a consortium to monitor all ethical aspects of the research, to ensure that the resulting product will be safe and efficacious for use in children from birth.


'/>"/>

Contact: Amy Pullan
a.l.pullan@sheffield.ac.uk
44-114-222-9859
University of Sheffield
Source:Eurekalert

Related medicine news :

1. NCH CIRP awarded CDC Injury Control Research Center designation, another 5 years
2. Individualized care best for lymphedema patients, MU researcher says
3. UH students spent summer making a difference with hands-on research
4. BUSM/VA researchers uncover gender differences in the effects of long-term alcoholism
5. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
6. Excellence Initiative winner TU München invests in the future: Young researchers
7. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
8. Clemson researchers collect and reuse enzymes while maintaining bioactivity
9. Genetic Research Sheds Light on Jewish Diaspora
10. Lawson research suggests breast cancer cells have discerning tastes
11. Clemson researcher awarded nearly $245,000 to study automation trust and dependence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced ... in people with addiction who are served by MAP’s patient engagement ecosystem. Lief ... that monitors heart and breath rates to identify anxiety levels and can provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her timeless ... news for single women is that she put all the words in her new ... Joan's insight, personal experiences and sparkling sense of humor have inspired her to write ...
(Date:4/24/2017)... KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... health topics, but she has not found any of them to be very practical. ... actions to slowly and easily make changes in their health. It prompted her in ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... “Learning to ... to navigate life. “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” ... for various nonprofits, former Chairman of the Board of Directors for CONTACT USA, and ...
(Date:4/24/2017)... ... , ... Life of Purpose Treatment is proud to present “An Evening for ... 7:30 pm on May 10th at the University Auditorium. , This benefit concert, featuring ... the UF Collegiate Recovery Community (UFCRC). The concert will kick off the 5th Annual ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
Breaking Medicine Technology: